The cerebral cavernous malformation pathway controls embryonic endocardial gene expression through regulation of MEKK3 signaling and KLF expression

Zinan Zhou1*, David Rawnsley1*, Lauren Goddard1, Wei Pan1, Xing-Jun Cao2, Zoltan Jakus1,9, Hui Zheng1, Jisheng Yang1, Simon Arthur3, Kevin J. Whitehead4, Dean Li4,5, Bin Zhou6, Benjamin A. Garcia2, Xiangjian Zheng1,7, and Mark L. Kahn8

1Department of Medicine and Cardiovascular Institute, University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA.
2Department of Biochemistry and Biophysics, University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA.
3Division of Cell Signaling and Immunology, University of Dundee, Dundee DD1 5EH, UK.
4Division of Cardiovascular Medicine and the Program in Molecular Medicine, University of Utah, Salt Lake City, UT 84112, USA.
5Division of Cardiovascular Medicine and the Program in Molecular Medicine, University of Utah, Salt Lake City, UT 84112, USA; The Key Laboratory for Human Disease Gene Study of Sichuan Province, Institute of Laboratory Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, China.
6Department of Genetics, Pediatric, and Medicine (Cardiology) and Wilf Cardiovascular Research Institute, Albert Einstein College of Medicine of Yeshiva University, 1301 Morris Park Avenue, Bronx, NY 10461, USA.
7Department of Medicine and Cardiovascular Institute, University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA; Lab of Cardiovascular Signaling, Centenary Institute, Sydney NSW 2050, Australia.
8Department of Medicine and Cardiovascular Institute, University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA.
9Present address: MTA-SE Lendulet Lymphatic Physiology Research Group of the Hungarian Academy of Sciences and the Semmelweis University, 1094 Budapest, Hungary

*These authors contributed equally
Correspondence should be addressed to: X.Z. (email: x.zheng@centenary.org.au) Telephone: 61-2-9565-6235 FAX: 61-2-9565-6101 or M.L.K. (email: markkahn@mail.med.upenn.edu) Telephone: 215-898-9007 FAX: 215-573-2094
SUMMARY

The cerebral cavernous malformation (CCM) pathway is required in endothelial cells for normal cardiovascular development and to prevent postnatal vascular malformations, but its molecular effectors are not well defined. Here we show that loss of CCM signaling in endocardial cells results in mid-gestation heart failure associated with premature degradation of cardiac jelly. CCM deficiency dramatically alters endocardial and endothelial gene expression, including increased expression of the Klf2 and Klf4 transcription factors and the Adamts4 and Adamts5 proteases that degrade cardiac jelly. These changes in gene expression result from increased activity of MEKK3, a mitogen-activated protein kinase that binds CCM2 in endothelial cells. MEKK3 is both necessary and sufficient for expression of these genes, and partial loss of MEKK3 rescues cardiac defects in CCM-deficient embryos. These findings reveal a molecular mechanism by which CCM signaling controls endothelial gene expression during cardiovascular development that may also underlie CCM formation.
INTRODUCTION

Embryonic heart growth requires the coordinated expansion and patterning of two major cell types, endothelial cells that line the lumen of the cardiac chambers and contractile myocardial cells that pump blood. These cell types support and interact with each other through secreted factors, i.e. endocardial-secreted growth factors such as neuregulin and FGFs that stimulate myocardial proliferation (Gassmann et al., 1995; Lavine et al., 2005) and myocardial-derived factors such as angiopoietin (Jeansson et al., 2011) that support endocardial growth. Loss of endocardial-myocardial signaling results in a failure of cardiac growth and embryonic lethality (Gassmann et al., 1995). Similar phenotypes arise in human patients with cardiac non-compaction (Jenni et al., 1999).

During the early, most rapid period of cardiac growth (E8.5-E14.5 in the mouse), abundant extracellular matrix known collectively as cardiac jelly separates the endocardium and myocardium (Nakamura and Manasek, 1981). Cardiac jelly consists of glycoaminoglycans such as hyaluronic acid (HA), and HA-binding proteins such as versican. Loss of either HA synthase or versican results in a thin myocardium that fails to proliferate and form normal trabeculae (Camenisch et al., 2000; Yamamura et al., 1997). As the heart matures and trabeculation is completed, cardiac jelly is lost and myocardial proliferation slows. Recent genetic studies in mice have implicated endocardial expression of secreted proteases such as ADAMTS1 and ADAMTS5 that degrade versican in the regulation of cardiac jelly and heart valve formation (Dupuis et al., 2011; Stankunas et al., 2008), but the upstream signaling pathways that control endothelial expression of such proteases and thereby regulate cardiac growth remain largely unknown.
The cerebral cavernous malformation (CCM) signaling pathway was discovered through genetic studies of human patients with familial vascular malformations (Chan et al., 2010; Riant et al., 2010). These studies have identified loss of function mutations in three genes, \textit{KRIT1}, \textit{CCM2} and \textit{PDCD10} (reviewed in Riant et al., 2010) that encode intracellular adaptor proteins that associate to form a biochemical complex with the transmembrane protein Heart of Glass (HEG1) (Kleaveland et al., 2009; Zheng et al., 2010). Conditional deletion studies in mice have demonstrated that KRIT1 and CCM2 are required in endothelial cells for branchial arch artery formation at E8.5-9 (Whitehead et al., 2009; Whitehead et al., 2004; Zheng et al., 2010), and to prevent CCM formation in the central nervous system of postnatal animals (Boulday et al., 2011; Chan et al., 2011; McDonald et al., 2011). How CCM signaling regulates endothelial and vascular function remains unclear. Cell culture studies and pharmacologic studies in mice have linked CCM signaling to negative regulation of RhoA activity (Glading et al., 2007; Stockton et al., 2010; Whitehead et al., 2009; Zheng et al., 2010) and TGFβ (Maddaluno et al., 2013), but definitive evidence for a causal relationship to these pathways or other downstream CCM effectors that clearly explain the pathway’s function in vascular development and maintenance has been lacking.

A role for CCM signaling in the developing heart was first revealed by zebrafish embryos lacking \textit{heg1}, \textit{krit1}, \textit{ccm2}, and \textit{pdc10} that exhibited a characteristic dilated heart phenotype (Mably et al., 2006; Mably et al., 2003; Zheng et al., 2010). In the developing mouse, \textit{Heg} is strongly expressed in the endocardium and its loss results in patchy areas of thin myocardium and cardiac rupture in late gestation (Kleaveland et al., 2009; Zheng et al., 2012). We have also recently identified a CCM2 orthologue,
CCM2L, that is expressed selectively in the endocardium of the developing heart where it regulates cardiac growth (Zheng et al., 2012). A major impediment to defining the role of the CCM pathway in cardiac development in mice has been early lethality due to vascular defects that prevent blood circulation. In the present study we use an Nfatc1Cre allele to delete CCM pathway genes specifically in the endocardium and bypass this vascular requirement (Wu et al., 2012). We find that loss of endocardial CCM signaling results in embryonic heart failure and reduced myocardial growth that is characterized by loss of cardiac jelly and preserved expression of endocardial growth factors. This phenotype is caused by increased expression of the Klf2 and Klf4 transcription factors and the Adamts4 and Adamts5 proteases that degrade the cardiac jelly protein versican. CCM-deficient endothelial gene expression changes are associated with increased activity of the MEKK3 signaling pathway, and CCM-deficient changes in cultured endothelial cells and embryonic mouse and fish hearts are rescued by reduced MEKK3 expression or activity. These studies define regulation of MEKK3 signaling and endothelial gene expression as a conserved mechanism by which CCM signaling functions in the developing heart, and raise the possibility that loss of this molecular regulatory mechanism may also participate in CCM formation.
RESULTS

*Nfatc1*<sup>Cre</sup> drives recombination in the endocardium but not in the endothelium of developing BAA\(s\) or peripheral vessels

Previous studies of global and endothelial-specific loss of *Krit1* and *Ccm2* revealed embryonic lethality at E8.5-9.5 due to a lack of lumenized branchial arch arteries (BAA\(s\)) and blood circulation (Boulday et al., 2009; Whitehead et al., 2009; Whitehead et al., 2004; Zheng et al., 2010), a severe vascular phenotype that was also observed in zebrafish embryos lacking HEG-CCM signaling (Zheng et al., 2010). Cardiac defects, such as atrial enlargement, reduced trabeculation and pericardial edema, were noted in deficient mouse embryos (Boulday et al., 2009; Whitehead et al., 2004), but since these changes arose in animals with complete vascular disruption it was not clear if they were primary or secondary phenotypes.

To circumvent the early requirement for CCM signaling in the BAA endothelium and investigate the role of CCM signaling specifically in the heart, we used *Nfatc1*<sup>Cre</sup> mice (Wu et al., 2012). Consistent with published studies, lineage tracing studies in *Nfatc1*<sup>Cre</sup>;R26R-\text{YFP} animals revealed *Nfatc1*<sup>Cre</sup> activity throughout the atrial and ventricular endocardium, but not in the endothelium of the distal aortic sac or the developing BAA\(s\) at E10.5 (Fig. S1A-F). *Nfatc1*<sup>Cre</sup> activity was observed in endothelial cells of the ascending aorta and proximal pulmonary arteries at E14.5, but not in more distal great vessels at that timepoint (Fig. S1G-K) or in the endothelial cells of the peripheral vasculature in the liver or kidney at P1 (Fig. S1L-R). These studies suggested that *Nfatc1*<sup>Cre</sup> could be used to test the requirement for CCM signaling specifically within the endocardium of the developing heart.
Endocardial deletion of Krit1 results in mid-gestation heart failure associated with loss of cardiac jelly.

Analysis of Nfatc1Cre;Krit1β/++; Krit1β/β crosses at P0.5 revealed that Nfatc1Cre;Krit1β/β mice die prior to birth (Supp. Table 1). Timed matings demonstrated live Nfatc1Cre;Krit1β/β embryos that were grossly indistinguishable from littermate controls at E12.5 (Fig. S2), but all Nfatc1Cre;Krit1β/β embryos were dead by E14.5-15.5 (Fig. S2 and Table S1). Thus endocardial loss of KRIT1 results in embryonic lethality during mid-gestation.

To understand the cause of lethality, Nfatc1Cre;Krit1β/β and control littermates were examined at E10.5 and E12.5, timepoints prior to lethality. H-E staining of Nfatc1Cre;Krit1β/β hearts at E10.5 revealed thin myocardium and smaller myocardial trabeculae compared with littermate controls, despite the presence of abundant endocardial cells (Fig. 1A, B). These changes were more marked at E12.5, when control hearts had developed a thicker compact myocardium and well-developed trabeculae (Fig. 1C, D). Atrial and ventricular chamber dilatation, like that observed in ccm-deficient zebrafish embryos (e.g. Fig. 4 and (Mably et al., 2006; Mably et al., 2003)), were also observed in Nfatc1Cre;Krit1β/β embryos at E12.5 (e.g. Fig. 1C vs. 1D). Most striking was the reduction in space between the endocardium and myocardium that is occupied by cardiac jelly in Nfatc1Cre;Krit1β/β embryo hearts at E10.5 and E12.5 (Fig. 1A-D). This phenotype was particularly evident in the trabeculae, where the myocardium was wrapped tightly by endocardium in the Nfatc1Cre;Krit1β/β heart but clearly separated from the endocardium in control hearts at these timepoints (arrows, Fig. 1A-D). Quantitation
of the area occupied by cardiac jelly in the trabeculae of the E10.5 heart revealed an
>65% decrease in Nfatc1\textsuperscript{Cre}\textsubscript{;}\textit{Krit1}\textsubscript{fl/fl} hearts compared with either Krit1\textsubscript{fl/fl} or
\textit{Nfatc1}\textsuperscript{Cre}\textsubscript{;}\textit{Krit1}\textsubscript{fl/+} littermate hearts (Fig. 1E).

The loss of endocardial-myocardial separation in \textit{Nfatc1}\textsuperscript{Cre}\textsubscript{;}\textit{Krit1}\textsubscript{fl/fl} hearts suggested that endocardial loss of CCM1 results in reduced cardiac matrix/jelly.
Consistent with this observation, Alcian blue staining demonstrated loss of matrix
glycosaminoglycans in the \textit{Nfatc1}\textsuperscript{Cre}\textsubscript{;}\textit{Krit1}\textsubscript{fl/fl} heart, particularly surrounding the
trabeculae at E10.5 (Fig. 1F, G). Versican is the major protein component of cardiac
jelly, and loss of versican results in reduced myocardial growth and failure to form
myocardial trabeculae. Immunostaining revealed a severe loss of intact versican in the
E10.5 \textit{Nfatc1}\textsuperscript{Cre}\textsubscript{;}\textit{Krit1}\textsubscript{fl/fl} heart compared with controls (Fig. 1H, I). Thus endocardial loss
of KRIT1 results in mid-gestation heart failure associated with reduced cardiac jelly.

\textbf{Endocardial loss of Ccm2 and Pdcd10 also result in loss of cardiac jelly.}

In the CCM signaling pathway KRIT1 binds CCM2 and CCM2 binds PDCD10 to
form a ternary complex (Hilder et al., 2007; Zawistowski et al., 2005; Zhang et al., 2007),
and deficiency of any of these three proteins results in CCM formation in human patients
and in mouse models of postnatal endothelial deficiency (Boulday et al., 2009; Boulday
et al., 2011; Whitehead et al., 2009; Whitehead et al., 2004). However, KRIT1 also
regulates integrin affinity through its interaction with ICAP1 (Liu et al., 2013) and binds
RAP1 (Serebriiskii et al., 1997). Thus the role of KRIT1 in the endocardium of the
developing heart might not simply reflect the role for CCM signaling in that cell type. To
test whether the cardiac abnormalities described above arise due to loss of canonical
CCM signaling in the endocardium, we deleted Ccm2 and Pdcd10 in the endocardium using Nfatc1\textsuperscript{Cre}. Nfatc1\textsuperscript{Cre};Ccm2\textsuperscript{fl/fl} embryos exhibited embryonic lethality at the same timepoint as observed for Nfatc1\textsuperscript{Cre};Krit1\textsuperscript{fl/fl} embryos (Table S1). Nfatc1\textsuperscript{Cre};Ccm2\textsuperscript{fl/fl} embryos also exhibited similar reductions in cardiac jelly, myocardial growth, Alcian blue staining and cardiac versican at both E10.5 (Fig. 2A-F) and E12.5 (Fig. 2G-L).

Nfatc1\textsuperscript{Cre};Pdcd10\textsuperscript{fl/fl} embryos exhibited embryonic lethality that was later than that as observed for Nfatc1\textsuperscript{Cre};Krit1\textsuperscript{fl/fl} and Nfatc1\textsuperscript{Cre};Ccm2\textsuperscript{fl/fl} embryos (Table S1). Nfatc1\textsuperscript{Cre};Pdcd10\textsuperscript{fl/fl} embryos did not appear abnormal at E10.5, but reduced cardiac jelly, myocardial growth, Alcian blue staining and versican were observed at E12.5 (Fig. 2M-R), consistent with a milder presentation of the same phenotype. These findings suggest that all three primary components of the CCM signaling pathway function in the mid-gestation endocardium to maintain cardiac jelly and support cardiac growth.

\textit{Endocardial loss of KRIT1 is associated with changes in the expression of KLF2/4 transcription factors and ADAMTS4/5 proteases.}

The thin myocardium and reduced cardiac jelly observed in Nfatc1\textsuperscript{Cre};Krit1\textsuperscript{fl/fl} hearts could result from reduced endocardial expression of myocardial growth factors and components of the cardiac jelly such as hyluronic acid. Alternatively, endocardial CCM signaling might be required to prevent the expression of proteases such as those in the ADAMTS family that cleave versican and degrade cardiac jelly at later timepoints during cardiac development (Stankunas et al., 2008; Dupuis et al., 2011). To address these possible mechanisms we characterized gene expression in whole E10.5 Nfatc1\textsuperscript{Cre};Krit1\textsuperscript{fl/fl} and littermate control hearts using microarray and qPCR analysis. Microarray and qPCR
analysis revealed elevated levels of *Adamts4* and *Adamts5*, versican-degrading proteases, in addition to *Klf2* and *Klf4* and a number of known KLF2/4 target genes, including *Nos3, Aqp1, Jam2, Thbd*, and *Palmd* (Dekker et al., 2006; Parmar et al., 2006) (Fig. 3A, B & D). Reduced levels of *Dll4* and *Tmem100*, genes previously associated with myocardial growth and trabeculation (Grego-Bessa et al., 2007; Somekawa et al., 2012), were also detected (Fig. 3A, C). Expression of the myocardial growth factors FGF9, FGF12 and FGF16 (Lavine et al., 2005) was unaltered, while that of neuregulin was elevated in E10.5 *Nfatc1Cre;Krit1^fl/fl* hearts (Fig. 3C), indicating that reduced myocardial growth did not result from reduced endocardial expression of growth factors. The expression of *Versican* and *HA synthase* were also unchanged, despite the dramatic loss of versican protein detected in *Nfatc1Cre;Krit1^fl/fl* hearts (Fig. 3D). In situ hybridization confirmed the increase in *Klf2* mRNA in the E10.5 *Nfatc1Cre;Krit1^fl/fl* heart (Fig. 3E). KLF4 protein was not detected in the endocardium of the heart chamber in control animals at E10.5, but was present in the nuclei of almost all the endocardial cells in the E10.5 *Nfatc1Cre;Krit1^fl/fl* heart (Fig. 3F). Increased levels of KLF2 protein were also detected by western blot analysis of the E10.5 *Nfatc1Cre;Krit1^fl/fl* heart (Fig. 3G).

Significantly, similar changes in *Klf* and *Adams* gene expression were observed in the E11.5 *Nfatc1Cre;Pdcd10^fl/fl* heart (Fig. S2), consistent with a requirement for canonical CCM signaling in the regulation of these genes.

The gene expression studies described above suggested that excess ADAMTS4/5 activity might be the cause of reduced versican and cardiac jelly in *Nfatc1Cre;Krit1^fl/fl* hearts. To detect ADAMTS-mediated breakdown of versican we stained *Nfatc1Cre;Krit1^fl/fl* and control E10.5 hearts with antibodies that specifically recognize a
versican epitope that is exposed following cleavage by ADAMTS proteases (“DPEAAE” antibody) (Sandy et al., 2001). Despite the nearly complete loss of intact versican (Fig. 1H, I), increased levels of ADAMTS-cleaved versican were detected in the E10.5 Nfatc1Cre;Krit1fl/fl heart by immunostaining with DPEAAE antibody (Fig. 3H). Biochemical analysis of whole E10.5 Nfatc1Cre;Krit1fl/fl hearts confirmed a marked increase in the levels of cleaved versican and ADAMTS5 protease (Fig. 3I). These findings tie the loss of cardiac jelly associated with endocardial loss of CCM signaling to changes in endocardial gene expression.

**Loss of klf2 or adams5 rescues loss of CCM signaling in zebrafish embryos.**

Endocardial-specific loss of CCM signaling in the mouse results in a thin, dilated heart that lacks cardiac jelly/matrix (Figs. 1 & 2). This phenotype resembles the dilated heart in zebrafish embryos lacking this pathway (Mably et al., 2006; Mably et al., 2003), suggestive of a conserved role for CCM signaling in vertebrate cardiac development. To determine if loss of CCM signaling results in loss of cardiac jelly/matrix in developing fish as well as mice we analyzed sections of 72 hpf ccm2 mutant and control littermate hearts using H-E and Alcian blue staining. Control hearts exhibited a multicellular layer of myocardium, with detectable Alcian blue-stained cardiac jelly between the endocardial and myocardial cell layers (Fig. 4A, B, C). In contrast, ccm2 mutant hearts exhibited a thin, single-cell layer of myocardium, and no Alcian blue staining was detected in sections that sampled the entire heart (Fig. 4D, E, F, N=4 embryos studied for each genotype). Thus CCM signaling deficiency results in the loss of cardiac jelly in both fish
and mouse embryos, consistent with a conserved role for this pathway during heart development.

Molecular analysis of E10.5 Nfatc1^{Cre};Krit1^{flo/flo} and E10.5 Nfatc1^{Cre};Pdcd10^{flo/flo} mouse hearts revealed significant up-regulation of Klf2/4 and Adamts4/5 gene expression, suggesting that these genes might play causal roles in the cardiac phenotype. To functionally test a conserved role for regulation of KLF2 and ADAMTS5 by CCM signaling we next studied 72 hpf zebrafish embryos following injection of morpholinos to block expression of krit1, with or without co-injection of morpholinos to block klf2a and klf2b (the two zebrafish Klf2 orthologues) or adams5 (the sole zebrafish Adamts5 orthologue). krit1 morpholinos resulted in a dilated heart in approximately 80% of embryos at 72 hpf (Fig. 4G, J). When combined with low dose klf2a/b morpholinos (1.5 ng each) that resulted in a reduction of approximately 50% in klf2 dosage (Fig. S3), we observed highly efficient rescue of the big heart phenotype (approximately 90% rescue efficiency, P<0.001) (Fig. 4H, J). Co-injection of morpholinos targeting the exon 2 splice acceptor and donor sites of adams5 (5+1 ng, a combination chosen to minimize morpholino dose and toxicity, Supp. Fig. 4C, D) also resulted in a significant rescue of the big heart phenotype (approximately 50% rescue efficiency, P<0.001) (Fig. 4I, J). To ensure that rescue was not merely due to interference with krit1 morpholinos, klf2 or adams5 morpholinos were injected into embryos generated by ccm2^{+/-} intercrosses. As expected, a big heart phenotype was observed in approximately 25% of control offspring at 72 hpf (Fig. 4K). However, this cardiac phenotype was observed in only 7% and 16% of offspring injected with klf2a/b or adams5 morpholinos respectively (indicative of a 70% and 35% rescue efficiency for klf2 and adams5 respectively; P<0.01 and P<0.05)
(Fig. 4K). The lower efficiency of mutant rescue compared with morphant rescue most likely reflects the greater loss of CCM signaling in ccm2<sup>-/-</sup> mutants compared with krit1 morphants. These studies suggest that a critical and conserved role of CCM signaling in the developing heart is to negatively regulate the expression of Klf2 and Adams5.

**MEKK3 regulates KLF and ADAMTS gene expression in cultured endothelial cells and in embryonic endocardium.**

The findings described above revealed that CCM signaling negatively regulates Klf2 and Adams5 gene expression, but studies of signaling by the CCM adaptor proteins have not defined a transcriptional mechanism of action. How are these pathways linked? MEKK3 was identified as a CCM2 binding partner a decade ago (Uhlik et al., 2003), and MEKK3 signaling is known to regulate gene expression through downstream effectors such as ERK5 and MEF2C (Chao et al., 1999; Nakamura and Johnson, 2003), as well as p38 and JNK (Deacon and Blank, 1999; Nebreda and Porras, 2000). We therefore next explored the possibility that CCM signaling might alter expression of KLF2 and ADAMTS5 through effects on the MEKK3 pathway. Since available anti-CCM2 antibodies are unable to detect the protein in cultured endothelial cells, to determine if MEKK3 interacts with CCM proteins in endothelial cells we used tetracycline-regulable lentiviral vectors to express an BirA-MEKK3 fusion protein in hCMEC/D3 endothelial cells (Weksler et al., 2005) (Fig. S4). Using this approach MEKK3-interacting proteins were biotinylated in live endothelial cells (Roux et al., 2012). Biotinylated proteins were captured by streptavidin beads and subjected to mass spectrometry analysis. When BirA-MEKK3 was expressed at endogenous levels (4 ng/ml doxycycline, Fig. S4A), no
specific MEKK3-interacting proteins were identified (not shown), perhaps due to kinase inactivity. At slightly higher expression levels (8 ng/ml doxycycline) peptides from only 4 interacting proteins were identified (Fig. S4). The most abundant of these was CCM2 (Fig. S4E). KRIT1 was also detected at a lower level equivalent to that of TRAF7, an MEKK3-interacting protein previously identified using tandem affinity purification (Bouwmeester et al., 2004). A similar result was obtained when BirA-MEKK3 was expressed in primary HUVECs (Fig. S4F). These studies indicate that MEKK3 interacts with the CCM protein complex in live endothelial cells.

To determine if MEKK3 regulates endothelial gene expression in a manner that might explain the changes observed following loss of CCM signaling we next tested whether MEKK3 is sufficient and/or required for KLF and ADAMTS gene expression in cultured endothelial cells. Over-expression of MEKK3 using the doxycycline regulable system described above resulted in dose-dependent increases in the levels of KLF2 and KLF4 expression in hCMEC/D3 endothelial cells (Fig. 5A). To determine whether MEKK3 regulates KLF gene expression in response to more physiologic stimuli we tested the role of MEKK3 in endothelial responses to fluid flow. Flow and fluid shear forces are established regulators of KLF2 and KLF4 expression in endothelial cells ex vivo (Huddleson et al., 2004; Parmar et al., 2006; Sohn et al., 2005; Villarreal et al., 2010) and in humans (Dekker et al., 2006), mice (Dekker et al., 2006; Lee et al., 2006), chick (Groenendijk et al., 2005) and fish (Vermot et al., 2009) in vivo. Up-regulation of KLF2 in response to flow has been shown to be mediated by MEK5-ERK5 signaling (Li et al., 2008; Parmar et al., 2006), one of the pathways directly regulated by MEKK3 (Chao et al., 1999; Nakamura and Johnson, 2003). Consistent with prior studies
 Parmar et al., 2006; Sohn et al., 2005), human umbilical vein endothelial cells (HUVECs) exposed to laminar shear for 16 hours exhibited increased KLF2, KLF4 and ADAMTS4 expression (Fig. 5B). Transfection with siRNAs directed against MEKK3 that resulted in a 40% knockdown in MEKK3 expression blocked the rise in expression of KLF2, KLF4 and ADAMTS4 induced by flow (Fig. 5B). These studies reveal that KLF and ADAMTS expression are regulated by MEKK3 in cultured endothelial cells.

To determine whether MEKK3 also regulates these genes in the E10.5 heart we next generated Nfatc1Cre;Map3k3flo/- animals. Nfatc1Cre;Map3k3flo/- animals did not survive to birth, and timed matings revealed embryonic lethality prior to E12.5 (Table S1). Analysis of Nfatc1Cre;Map3k3flo/- embryonic heart sections revealed a thin myocardial cell layer with preserved cardiac jelly and normal endocardial-myocardial separation at E10.5 (Fig. S5A). In contrast to endocardial loss of CCM signaling, versican levels were preserved in the E10.5 Nfatc1Cre;Map3k3flo/- heart (Fig. S5B). Gene expression analysis of E10.5 Nfatc1Cre;Map3k3flo/- and control littermate hearts revealed severe (>90%) reductions in the expression of Klf2 and the known KLF2 target genes Nos3, Aqp1, Jam2, Thbd, and Palmd, as well as Klf4, Adams4 and Adams5 (Fig. 5C, D). FGF gene expression was unchanged but the expression of Nrg1 was severely reduced (Fig. 5D). Thus loss of MEKK3 confers gene expression changes that are precisely reciprocal to those conferred by loss of KRIT1 or PDCD10. To determine whether MEKK3 regulates Klf and Adams gene expression through the ERK5 MAPK pathway we cultured wild-type E10.5 explanted hearts in the presence of BIX02189, a highly specific inhibitor of MEK5, the MAPK2K that is activated by MEKK3 and in turn activates ERK5 (Tatake et al., 2008). Treatment with BIX02189 resulted in reduced levels of Klf2, Klf4 and
Adamts5 expression (Fig. 5E). These findings demonstrate that MEKK3 regulates KLF and ADAMTS gene expression in endothelial cells ex vivo and in endocardial cells in vivo through the MEK5-ERK5 MAPK pathway.

**Loss of MEKK3 rescues loss of CCM signaling in cultured endothelial cells and zebrafish embryo hearts.**

The reciprocal changes in gene expression observed with endocardial loss of CCM and MEKK3 signaling, the physical interaction between the CCM complex and MEKK3, and the preservation of Mekk3 gene expression in Nfatc1Cre;Krit1fl/fl hearts (Fig. S6A) suggested that CCM signaling might regulate endocardial gene expression by inhibiting MEKK3 function. To test the effect of loss of CCM signaling on MEKK3 function we used siRNA to knockdown CCM2 in HUVECs and examined downstream MEKK3 signaling through ERK5. HUVECs treated with CCM2 siRNA, but not with scrambled siRNA, exhibited increased phospho-ERK5 with no change in total ERK5 or GAPDH protein (Fig. 6A), consistent with an increase in MEKK3 pathway activity. As observed with endocardial deletion in the E10.5 mouse heart, loss of CCM2 in HUVEC conferred increased expression of KLF2, KLF4 and ADAMTS4 (Fig. 6B-D). These increases were reversed by simultaneous knockdown of MEKK3, consistent with CCM regulation of gene expression through MEKK3.

To test whether increased MEKK3 signaling is causal for CCM-deficient phenotypes in vivo we first used morpholinos to reduce the levels of mkk3 in krit1 morphant and ccm2 mutant zebrafish embryos. krit1 morpholinos resulted in a dilated heart in approximately 65% of embryos at 72 hpf in these studies (Fig. 6E, F, H). When
combined with low dose morpholinos (3 ng) that resulted in a reduction of approximately 40% in mekk3 dosage (Fig. S7) but had no independent effect on cardiac development, we observed efficient (approx 75%) rescue of the krit1 morphant cardiac phenotype (P<0.001) (Fig. 6G, H). To ensure that rescue was not due to interference with krit1 morpholinos, mekk3 morpholinos were injected into embryos generated by ccm2+/− intercrosses. A big heart phenotype was observed in approximately 18% of control morpholino injected offspring at 72 hpf, and injection of low dose mekk3 morpholinos reduced this to approximately 6%, consistent with a 66% rescue efficiency (P<0.001, Fig. 6I). Thus loss of mekk3 rescues the dilated heart phenotype conferred by loss of either krit1 or ccm2 in zebrafish embryos, suggesting that gain of MEKK3 signaling may underlie the role of CCM signaling during cardiac development.

**Mekk3 haplo-insufficiency rescues the loss of cardiac jelly and changes in gene expression conferred by endocardial Krit1 deletion.**

Rescue of the big heart phenotype conferred by loss of CCM signaling with loss of mekk3 expression in the zebrafish requires careful dosing of mekk3 morpholinos to avoid an independent mekk3-deficient cardiac defect, and the ability to measure rescue using specific molecular and cellular endpoints is limited in the zebrafish embryo heart. To address these issues and rigorously test the causal role of the MEKK3 pathway as a downstream CCM effector in mammals we next tested the ability of loss of one Mekk3 allele to rescue the specific changes in cardiac jelly and cardiac gene expression in the E10.5 Nfatc1Cre;Krit1fl/fl mouse heart. Despite the expected loss in MEKK3 protein in Map3k3+/− hearts (Fig. S6C), Map3k3+/− animals and Nfatc1Cre;Map3k3fl/+ animals
develop normally, exhibit no changes in cardiac jelly, and have patterns of cardiac gene expression at E10.5 that are indistinguishable from Map3k3\textsuperscript{fl/fl} littermates (Yang et al., 2000 and data not shown). Thus loss of a single Mekk3 allele is well-tolerated and does not affect cardiac development. At E10.5 Nfatc1\textsuperscript{Cre};Krit1\textsuperscript{fl/fl};Map3k3\textsuperscript{fl/+} hearts exhibited significantly more cardiac jelly, alcian blue staining and intact versican than was seen in Nfatc1\textsuperscript{Cre};Krit1\textsuperscript{fl/fl};Map3k3\textsuperscript{fl/+} littermates (Fig. 7A-I). Quantitation of the area occupied by cardiac jelly in the trabeculae of E10.5 littermate hearts revealed a >65% decrease in Nfatc1\textsuperscript{Cre};Krit1\textsuperscript{fl/fl} hearts compared with control littermates, but only a 25% decrease in Nfatc1\textsuperscript{Cre};Krit1\textsuperscript{fl/fl};Map3k3\textsuperscript{fl/+} hearts (P<0.001, Fig. 7J). Consistent with the rescue of cardiac jelly, biochemical analysis of ADAMTS-proteolyzed versican using anti-DPEAAE antibodies revealed increased versican breakdown in the Nfatc1\textsuperscript{Cre};Krit1\textsuperscript{fl/fl} heart that was restored to normal levels in the Nfatc1\textsuperscript{Cre};Krit1\textsuperscript{fl/fl};Map3k3\textsuperscript{fl/+} heart (Fig. 7K). qPCR analysis of cardiac gene expression revealed significantly reduced levels of Klf2, Klf4, KLF2/4 target genes, Adams4 and Adams5, and Nrg1, and increased levels of Dll4 and Tmem100, in the Nfatc1\textsuperscript{Cre};Krit1\textsuperscript{fl/fl};Map3k3\textsuperscript{fl/+} heart compared with the Nfatc1\textsuperscript{Cre};Krit1\textsuperscript{fl/fl};Map3k3\textsuperscript{fl/+} heart (Fig. 7L-N). The levels of Klf2, Klf4 and Adams5 gene expression were not restored to normal in the Nfatc1\textsuperscript{Cre};Krit1\textsuperscript{fl/fl};Map3k3\textsuperscript{fl/+} heart, consistent with the significant but incomplete histologic rescue. Thus virtually all of the hallmark histologic, biochemical, and genetic changes observed with endocardial loss of KRIT1 are rescued by endocardial loss of MEKK3, indicating that gain of MEKK3 signaling plays a central, causal role in the endothelial phenotype conferred by loss of CCM signaling in the developing heart.
DISCUSSION

Genetic studies in humans, mice and fish have revealed that CCM signaling is required in endothelial cells for normal cardiovascular development and to prevent vascular malformations after birth, but the molecular basis for these phenotypes has remained elusive. We have used studies of cultured endothelial cells, endocardial-specific deletion in the developing mouse, and genetic rescue of the CCM-deficient heart phenotype in both mice and zebrafish to reveal a molecular mechanism by which the CCM pathway regulates endothelial gene expression. Our studies demonstrate that CCM signaling in the endocardium plays a critical and conserved role in cardiac development through regulation of the MEKK3 MAPK signaling pathway and downstream ADAMTS and KLF gene expression.

A role for CCM signaling in cardiac development was revealed by the dilated heart phenotype observed in zebrafish embryos lacking this pathway (Mably et al., 2006; Mably et al., 2003; Zheng et al., 2010), but the molecular and cellular basis for this phenotype has been unclear. The studies reported here demonstrate that CCM signaling controls degradation of cardiac jelly by negatively regulating endocardial expression of ADAMTS4/5 and KLF2/4. A causal role for excess ADAMTS4/5 is demonstrated by a dramatic increase in versican cleavage associated with loss of cardiac jelly in the \( Nfatc1^{Cre}\cdot Krit1^{fl/fl} \) mouse heart and by rescue of the zebrafish dilated heart with morpholinos that reduced \( adamts5 \) levels. Expression of both \( Adamts \) and \( Klf \) genes is severely reduced following endothelial loss of MEKK3 in vitro and in vivo, increased MEKK3 drives expression of both genes in cultured endothelial cells, rescue of \( krit1 \) morphant and \( ccm2 \) mutant zebrafish hearts was highly efficient with loss of \( mekk3, klf2 \)
or \textit{adamts5}, and both the histologic and molecular phenotypes conferred by loss of endocardial CCM signaling are rescued by partial loss of MEKK3. Thus a straightforward pathway is one in which changes in MEKK3 signaling alter expression of KLF2/4 that in turn controls expression of ADAMTS4/5 (Fig. 7O). However, \textit{Adamts5} has not been identified as a KLF2 target gene in cultured endothelial cells (Dekker et al., 2002; Parmar et al., 2005), and we do not detect \textit{Adamts5} expression in HUVEC. Thus \textit{Adamts4/5} may be regulated by MEKK3 in a KLF-independent manner, or by KLF2/4 in embryonic endocardium but not in cultured endothelial cells. It is also likely that MEKK3-regulated and KLF-regulated genes other than \textit{Adamts4/5} contribute to the cardiac phenotype associated with CCM deficiency. Two such candidates identified by our gene expression studies are \textit{Dll4}, a Notch ligand expressed by the endocardium that supports trabeculation and myocardial proliferation (Grego-Bessa et al., 2007), and \textit{Tmem100}, an ALK1 target gene that is also specifically expressed in the endocardium and required for cardiac growth (Somekawa et al., 2012). In this regard it is intriguing that KLF4 has recently been shown to repress Dll4 expression in endothelial cells (Hale et al., 2014).

A key finding to emerge from our studies is the identification of a molecular mechanism by which CCM signaling regulates endothelial gene expression. Previous studies of the CCM pathway have not revealed a molecular path to transcriptional regulation, although changes in RhoA activity (Glading et al., 2007; Stockton et al., 2010; Whitehead et al., 2009; Zheng et al., 2010) and TGFβ signaling (Maddaluno et al., 2013) have been reported. The findings that CCM2 interacts with MEKK3 in endothelial cells and that endocardial loss of CCM signaling and MEKK3 confer precisely reciprocal
changes in gene expression suggested that the CCM pathway may control gene expression by regulating MEKK3 signaling (Fig. 7O). Rescue of CCM-deficient phenotypes in cultured endothelial cells and fish and mouse embryos demonstrates a clear causal role for increased MEKK3 function. Previous studies have linked MEKK3 to three downstream MAPK pathways by which it might regulate gene expression: JNK (Deacon and Blank, 1999), p38 (Deacon and Blank, 1999; Uhlik et al., 2003) and ERK5 (Chao et al., 1999; Nakamura and Johnson, 2003). However, our endothelial studies demonstrate MEKK3 regulation of KLF2/4 and ADAMTS4 expression in response to fluid flow, known to be downstream of MEK5 and ERK5 (Li et al., 2008; Parmar et al., 2006; Sohn et al., 2005), and ex vivo embryonic heart culture studies using a highly specific MEK5 inhibitor identify the MEK5-ERK5 pathway as a key mechanism of gene regulation by CCM signaling (Fig. 5). Thus our studies support a mechanism in which CCM signaling specifically regulates the MEK5-ERK5 pathway downstream of MEKK3 in endothelial cells.

A final question raised by our studies is whether regulation of the MEKK3 pathway by CCM signaling observed in the developing heart also plays an important role in the formation of CCMs in humans and mice. Loss of CCM signaling in the postnatal endothelium results in large vascular malformations (CCMs) in the central nervous of humans and mice (Akers et al., 2009; Boulday et al., 2011; Chan et al., 2011; McDonald et al., 2011). CCMs are an important cause of stroke for which there is presently no medical treatment (Li and Whitehead, 2010). Drugs that inhibit RhoA and TGFb signaling have been reported to reduce lesion frequency in mouse models of CCM (Maddaluno et al., 2013; McDonald et al., 2012), but the responses have been incomplete
and a clear molecular and/or cellular basis for CCM formation is still lacking. Significantly, up-regulation of KLF4 expression was recently identified as a prominent molecular phenotype of the endothelial cells that form CCMs (Maddaluno et al., 2013), a finding that mirrors the increase in KLF4 observed in the developing endocardium and in cultured endothelial cells lacking CCM signaling. It is therefore possible that CCM-deficient endothelial cells in the central nervous system exhibit increased MEKK3 activity like that we have observed in CCM-deficient endocardial cells, and that changes in gene expression resulting from increased MEKK3 activity also underlie CCM disease pathogenesis. Future studies that test rescue of CCM formation in mice using either genetic or pharmacologic loss of MEKK3 pathway activity should be able to test this clinically important hypothesis.
EXPERIMENTAL PROCEDURES

Mice

Nfatc1<sup>Cre</sup> (Wu et al., 2012), Ccm2<sup>fl/fl</sup> (Zheng et al., 2012), Pdc<sup>10<sub>fl/fl</sub></sup> (Chan et al, 2010) and Krit1<sup>fl/fl</sup> (Mleynek et al., 2014) animals have been previously described. The ROSA26-YFP reporter line was obtained from Jackson Laboratories (#006148). Map3k3<sup>fl/fl</sup> animals were generated as shown in Fig. S6. The University of Pennsylvania Institutional Animal Care and Use Committee approved all animal protocols.

Histology

Embryos and tissues were fixed in 10% formaldehyde overnight, dehydrated in 100% ethanol, and embedded in paraffin. 8 µm thick sections were used for hematoxylin eosin, Alcian blue and immunohistochemistry staining. Klf2 in situ hybridization was performed as previously reported (Lee et al., 2006). The following antibodies were used for immunostaining: rat anti-Pecam (1:500, BD PharMingen), rabbit anti-Versican (1:200, Millipore), rabbit anti-DPEAAE (1:200, Pierce-Antibodies).

Zebrfish studies

Zebrafish were maintained and with approval of the Institutional Animal Care and Use Committee of the University of Pennsylvania. ccm2<sup>hi296</sup> mutant zebrafish were obtained from the Zebrafish International Resource Center (ZIRC). i-fabp:GFP transgenic embryos in which the heart is fluorescently labeled were kindly provided by Dr. Michael Pack. The cardiac reporter zebrafish were created by transposon-based gene trap approach using the 192bp zebrafish I-FABP promoter (Her et al., 2004). Morpholino
oligonucleotides were obtained from Gene Tools (Philomath, OR) and were injected into the yolk of one-cell stage embryos at the indicated dosages and combinations. The morpholino sequences are described in Supplemental Experimental Procedures.

**Biochemical studies.**

Biochemical studies of E10.5 \( Nfatc1^{Cre}\), \( Krit1^{flo/flo} \) hearts were performed as previously described (Kleaveland et al., 2009; Zheng et al., 2010). The following antibodies were used for immunonlotting: rabbit anti-Gapdh (1:5000, Cell Signaling), rabbit anti-pERK5 (1:1000, Cell Signaling), rabbit anti-Adamts5 (1:1000, Abcam), rabbit anti-DPEAAE (1:1000, Pierce-Antibodies). Identification of BirA-MEKK3 interacting proteins is described in Supplemental Materials and Methods.

**Endothelial cell studies**

Human umbilical vein endothelial cells (HUVEC; Lonza) were grown in EBM media supplemented with EGM-2 SingleQuots (Lonza). HUVECs were transfected overnight with 10nM Ambion Silencer Select siRNA against Map3k3 (s8671, Invitrogen) or Ccm2 (s8671, Invitrogen) using siPORT Amine Transfection Agent (Invitrogen) according to the manufacturer’s protocol. 72 hours after transfection, total RNA was isolated using TRIzol Reagent (Invitrogen). cDNA was generated from 1 μg total RNA using Superscript III Reverse Transcriptase (Invitrogen). qPCR was performed in Power SYBR Green PCR Master Mix (Applied Biosciences) using primers described in Supplemental Materials and Methods.
**Mouse heart explant studies**

Hearts from wild type embryos on mixed background were collected at E10.5 and cultured in the presence of BIX02189 (5 μM) or DMSO for 24 h on transwell filters as described previously (Lavine et al., 2005).

**Statistics**

*P* values were calculated using an unpaired 2-tailed Student’s t-test, ANOVA, or Chi Square analysis as indicated. The mean and standard error of mean (SEM) are shown in the bar graphs.
Author Contributions

ZZ and DR designed and performed most of the experiments and helped write the manuscript. SA, KW, DL, and BZ provided critical reagents. LG, WP, XC, ZJ, HZ, JY, XJ, BG and MK helped design and perform the experiments and wrote the manuscript.

Acknowledgements

We thank the members of the Kahn lab for their thoughtful comments during the course of this work. We thank Drs. Babette Weksler, Pierre-Olivier Couraud and Ignacio Romero for providing the hCMEC/D3 endothelial cells. These studies were supported by National Institute of Health grants R01HL094326 (MLK), R01HL102138 (MLK), R01NS075168 (KW), T32HL007971 (DR), and American Heart Association grant 11SDG7430025 (XZ).
References


brain barrier-specific properties of a human adult brain endothelial cell line. Faseb J 19, 1872-1874.


Figure Legends

Figure 1. Lack of endocardial Krit1 results in loss of cardiac jelly. A-D.

Nfatc1Cre;Krit1fl/fl hearts exhibit thinned myocardium and reduced space between endocardial and myocardial cells at E10.5 and E12.5. Arrows indicate the endocardial-myocardial gap. A’-D’ show higher magnification images of the regions boxed in A-D.

E. Ratio of the area occupied by cardiac jelly to that occupied by myocardium in the trabeculae of E10.5 littermate hearts. N=3 embryos; 9 sections analyzed for each group. ** indicates P<0.01. F, G. Reduced Alcian blue staining in Nfatc1Cre;Krit1fl/fl hearts at E10.5. F’ and G’ show higher magnification images of the regions boxed in F and G. H, I. Immunostaining for versican in Nfatc1Cre;Krit1fl/fl and control hearts at E10.5. H’ and I’ show higher magnification images of the regions boxed in H and I. Scale bars indicate 100 μm.

Figure 2. Endocardial loss of Ccm2 or Pdcd10 also results in reduced cardiac jelly.

A, B. Thin myocardium and reduced endocardial-myocardial space in Nfatc1Cre;Ccm2fl/fl hearts at E10.5. A’ and B’ show higher magnification images of the regions boxed in A and B. C, D. Reduced Alcian blue staining in Nfatc1Cre;Ccm2fl/fl hearts at E10.5. E, F. Reduced intact versican in in Nfatc1Cre;Ccm2fl/fl hearts at E10.5. G, H. Thin myocardium and reduced endocardial-myocardial space in Nfatc1Cre;Ccm2fl/fl hearts at E12.5. G’ and H’ show higher magnification images of the regions boxed in G and H. I, J. Reduced Alcian blue staining in Nfatc1Cre;Ccm2fl/fl hearts at E12.5. K, L. Reduced intact versican in Nfatc1Cre;Ccm2fl/fl hearts at E12.5. M, N. Thin myocardium and reduced
endocardial-myocardial space in \(Nfatc1^{Cre};Pdcd10^{fl/fl}\) hearts at E12.5. M' and N’ show higher magnification images of the regions boxed in M and N. O, P. Reduced Alcian blue staining in \(Nfatc1^{Cre};Pdcd10^{fl/fl}\) hearts at E12.5. Q, R. Reduced intact versican in \(Nfatc1^{Cre};Pdcd10^{fl/fl}\) hearts at E12.5. Scale bars indicate 100 μm.

**Figure 3.** Loss of CCM signaling results in increased **Klf2** and **Adamts5** expression and function. A. Microarray analysis of mRNA expression in E10.5 \(Nfatc1^{Cre};Krit1^{fl/+}\) and \(Krit1^{fl/+}\) littermate hearts reveals increased levels of **Klf2**, **Klf4**, KLF2 target genes and **Adamts5**, and reduced levels of **Dll4** and **Tmem100**. N= 4 for both genotypes. B. qPCR of E10.5 hearts reveals preserved or increased expression of **Nrg1** and FGF growth factors following endocardial **Krit1** loss. C. qPCR of E10.5 hearts reveals elevated levels of **Klf2** and established KLF2 target genes following endocardial **Krit1** loss. D. qPCR analysis of genes associated with cardiac jelly matrix proteins and matrix-degrading proteases in E10.5 hearts reveals elevated levels of **Adamts5** following endocardial **Krit1** loss. N= 3 for **Krit1^{fl/+}\), N= 4 for \(Nfatc1^{Cre};Krit1^{fl/+}\), N=5 for \(Nfatc1^{Cre};Krit1^{fl/fl}\) in B-D. E. In situ hybridization for **Klf2** in E10.5 \(Nfatc1^{Cre};Krit1^{fl/+}\) and **Krit1^{fl/+}\) littermate hearts. F. Immunostaining for KLF4 protein (arrows) and myocardium (MF20) in E10.5 \(Nfatc1^{Cre};Krit1^{fl/+}\) and **Krit1^{fl/+}\) littermate hearts. G. Immunoblot analysis of KLF2 protein in whole E10.5 \(Nfatc1^{Cre};Krit1^{fl/+}\) and \(Nfatc1^{Cre};Krit1^{fl/+}\) and **Krit1^{fl/+}\) littermate hearts. GAPDH is shown as a loading control. H. Immunostaining using anti-DPEAAE antibody to detect ADAMTS-cleaved versican reveals increased levels in the E10.5 \(Nfatc1^{Cre};Krit1^{fl/+}\) heart. Boxed regions are shown at higher magnification on the right. I. Immunoblot analysis of lysate derived from whole E10.5 hearts reveals increased levels
of cleaved versican (DPEAAE) and the ADAMTS5 protease with endocardial loss of Krit1. GAPDH is shown as a loading control. Scale bars indicate 100 μm. * indicates P < 0.05; ** indicates P<0.01; *** indicates P<0.001.

Figure 4. Loss of klf2 or adams5 rescues the cardiac phenotype conferred by loss of CCM signaling in zebrafish embryos. A-C. H-E and Alcian blue staining of adjacent sections from a 72 hpf control zebrafish heart reveal a myocardial wall with multiple cell layers (A) and the presence of Alcian blue-staining cardiac jelly (B, C). D-F. H-E and Alcian blue staining of adjacent sections from a 72 hpf ccm2 mutant heart reveals a thin myocardial wall (D) and lack of cardiac jelly (E, F). C and F are higher magnification images of the boxed regions in B and E respectively. G. Injection of zebrafish embryos with krit1 morpholinos results in a big heart at 72 hpf detected by light microscopy and in i-fabp:GFP transgenic embryos in which the heart is fluorescently labeled. H. Injection of morpholinos targeting both krit1 and the two klf2 zebrafish orthologues rescues the big heart phenotype at 72 hpf. I. Injection of morpholinos targeting both krit1 and adams5 rescues the big heart phenotype at 72 hpf. J. Efficiency of rescue of the krit1 morphant heart phenotype with klf2 and adams5 morpholinos. *** indicates P<0.001. K. Knockdown of klf2 or adams5 also rescues the cardiac phenotype in ccm2 mutant zebrafish embryos. The frequency of a big heart phenotype in the offspring of ccm2+/− intercrosses treated with control, klf2 or adams5 morpholinos is shown. ** indicates P<0.01; * indicates P<0.05. The number of total embryos analyzed and number experimental repeats (in parenthesis) in J and K are indicated above each bar. Scale bars indicate 100 μm.
Figure 5. MEKK3 regulates expression of KLF and ADAMTS genes in cultured endothelial cells and in the endocardium of the developing heart.  

A. Tetracycline-regulated expression of BirA-MEKK3 drives dose-dependent expression of KLF2 and KLF4 in HUVEC.  

B. siRNA knockdown of MEKK3 in HUVEC blocks flow-induced expression of KLF2, KLF4 and ADAMTS4. HUVEC were exposed to 16 hours of laminar shear after exposure to siRNA directed against MEKK3 (MAP3K3) or control, scrambled siRNA. N=5; P<0.0001.  

C. qPCR of E10.5 hearts reveals severely reduced levels of Klf2, Klf4 and known KLF2/4 target genes following endocardial Mekk3 (Map3k3) deletion. N= 3 for all groups.  

D. qPCR of E10.5 hearts reveals reduced levels of Nrg1 and Adams5 but normal levels of FGFs following endocardial Mekk3 (Map3k3) deletion. N= 3 for all groups.  

E. qPCR of E9.5 wild-type mouse hearts following 24 hour incubation in medium containing %WKH0.LQKLELWRU%:³%RU'062 ¹FRQWURO¹RU6DOOJURXSV * indicates P <0.05; ** indicates P<0.01; *** indicates P<0.001; **** indicates P<0.0001.

Figure 6. Loss of MEKK3 rescues the CCM-deficient phenotype in cultured endothelial cells and zebrafish embryos.  

A. siRNA knockdown of CCM2 increases the level of phospho-ERK5 in cultured HUVEC.  

B-D. siRNA knockdown of CCM2 increases the expression of KLF2, KLF4 and ADAMTS4 in HUVEC, and these changes in gene expression are reversed by siRNA knockdown of MEKK3 (MAP3K3).  

E, F. Injection of zebrafish embryos with krit1 morpholinos results in a big heart at 72 hpf in i-fabp:GFP transgenic embryos in which
the heart is fluorescently labeled. **G.** Injection of morpholinos targeting both \textit{krit1} and \textit{map3k3} rescues the big heart phenotype at 72 hpf. **H.** Efficiency of rescue of the \textit{krit1} morphant heart phenotype with \textit{map3k3} morpholinos. *** indicates $P<0.001$. **I.** Knockdown of \textit{map3k3} rescues the cardiac phenotype in \textit{ccm2} mutant zebrafish embryos. The frequency of a big heart phenotype in the offspring of \textit{ccm2} sup/+ intercrosses treated with control or \textit{map3k3} morpholinos is shown. *** indicates $P<0.001$. The number of total embryos analyzed and number experimental repeats (in parenthesis) are indicated above each bar in H and I. Scale bars indicate 100 $\mu$m.

**Figure 7. Reduced Mekk3 expression rescues the loss of cardiac jelly and changes in gene expression conferred by endocardial loss of Krit1.**

**A-C.** The endocardial-myocardial space occupied by cardiac jelly is increased in \textit{Nfatc1Cre;Krit1flo/flo;Map3k3flo/+} hearts compared with \textit{Nfatc1Cre;Krit1flo/flo;Map3k3+/+} littermates at E10.5. Higher magnification images of the boxed regions are shown on the right. **D-F.** Alcian blue staining for cardiac jelly is increased in \textit{Nfatc1Cre;Krit1flo/flo;Map3k3flo/+} hearts compared with \textit{Nfatc1Cre;Krit1flo/flo;Map3k3+/+} littermates at E10.5. **G-I.** Versican in cardiac jelly is increased in \textit{Nfatc1Cre;Krit1flo/flo;Map3k3flo/+} hearts compared with \textit{Nfatc1Cre;Krit1flo/flo;Map3k3+/+} littermates at E10.5. **J.** The ratio of the area occupied by cardiac jelly to that occupied by myocardium in the trabeculae is increased in E10.5 \textit{Nfatc1Cre;Krit1flo/flo;Map3k3flo/+} hearts compared with \textit{Nfatc1Cre;Krit1flo/flo;Map3k3+/+} littermates. N=3 embryos; 9 sections analyzed for each group. **K.** Immunoblot analysis of lysate derived from whole E10.5 hearts reveals higher levels of cleaved versican (DPEAAE) in
*NFATC1*Cre*;KRIT1<sup>fl/fl</sup>;Map3k3<sup>+/+</sup> hearts compared with *NFATC1*Cre*;KRIT1<sup>fl/fl</sup>;Map3k3<sup>+/+</sup> littermates. GAPDH is shown as a loading control. **L-N.** qPCR of E10.5 hearts reveals normalized expression of *Klf2, Klf4*, KLF2/4 target genes, *Nrg1, Dll4, Tmem100, Adams4* and *Adams5* in *NFATC1*Cre*;KRIT1<sup>fl/fl</sup>;Map3k3<sup>+/+</sup> hearts compared with *NFATC1*Cre*;KRIT1<sup>fl/fl</sup>;Map3k3<sup>+/+</sup> littermates at E10.5. * indicates P <0.05; ** indicates P<0.01; *** indicates P<0.001. Scale bars indicate 100 μm. **O.** CCM regulation of MEKK3 activity and gene expression. The CCM complex binds MEKK3 through interaction with CCM2 and blocks MEKK3 signaling (left). Loss of the CCM complex increases MEKK3-ERK5 signaling and the expression of *Klf2* and *Adams5*, resulting in the breakdown of cardiac jelly and reduced myocardial proliferation (right).
Figure 1

<table>
<thead>
<tr>
<th></th>
<th>E10.5</th>
<th>E12.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kntr1 flox/flox</td>
<td><img src="image" alt="A" /></td>
<td><img src="image" alt="C" /></td>
</tr>
<tr>
<td>NfatC1 Cre; Kntr1 flox/flox</td>
<td><img src="image" alt="A'" /></td>
<td><img src="image" alt="C'" /></td>
</tr>
</tbody>
</table>

![E](image)

- **E**
  - Area jelly:myocardium
  - Bar graphs showing the area ratio for each genotype: Kntr1 flox/flox, NfatC1 Cre; Kntr1 flox/flox, and NfatC1 Cre; Kntr1 flox/flox.

<table>
<thead>
<tr>
<th></th>
<th>Alcian Blue</th>
<th>Versican/PECAM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kntr1 flox/flox</td>
<td><img src="image" alt="F" /></td>
<td><img src="image" alt="H" /></td>
</tr>
<tr>
<td>NfatC1 Cre; Kntr1 flox/flox</td>
<td><img src="image" alt="F'" /></td>
<td><img src="image" alt="H'" /></td>
</tr>
</tbody>
</table>

![G](image) - ![G'](image)

![L](image) - ![L'](image)

![H](image) - ![H'](image)
Figure 2
Figure 3

A

B

C

D

E

F

G

H

I

**Krit1**+/+  **NfatC**<sup>Cre</sup>,**Krit1**+/+

**Krit1**fl/fl  **NfatC**<sup>Cre</sup>,**Krit1**fl/fl

**Kirit1**fl/fl  **NfatC**<sup>Cre</sup>,**Krit1**fl/fl

**Krit1**fl/fl  **NfatC**<sup>Cre</sup>,**Krit1**fl/fl

Apop1  Adanm5  Kif4  Kif2  Palmd  Jam2  Thbd  Lef1  Nrg1  Pdgfb  Hgo1  Nos3  Stab1  Emin1  Flt4  Dll4  Tmem100

**DAPI/Kif2**

**KLF4/MF20**

<table>
<thead>
<tr>
<th></th>
<th>Krit1fl/fl</th>
<th>NfatC&lt;sup&gt;Cre&lt;/sup&gt;,Krit1fl/+</th>
<th>NfatC&lt;sup&gt;Cre&lt;/sup&gt;,Krit1fl/fl</th>
</tr>
</thead>
<tbody>
<tr>
<td>KLF2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAPDH</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

KLF2  GAPDH

<table>
<thead>
<tr>
<th></th>
<th>Krit1fl/fl</th>
<th>NfatC&lt;sup&gt;Cre&lt;/sup&gt;,Krit1fl/+</th>
<th>NfatC&lt;sup&gt;Cre&lt;/sup&gt;,Krit1fl/fl</th>
</tr>
</thead>
<tbody>
<tr>
<td>KLF2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAPDH</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**DAPI/DPEAAE**

<table>
<thead>
<tr>
<th></th>
<th>Krit1fl/fl</th>
<th>NfatC&lt;sup&gt;Cre&lt;/sup&gt;,Krit1fl/+</th>
<th>NfatC&lt;sup&gt;Cre&lt;/sup&gt;,Krit1fl/fl</th>
</tr>
</thead>
<tbody>
<tr>
<td>KLF2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAPDH</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**DAPI/DPEAAE**

<table>
<thead>
<tr>
<th></th>
<th>Krit1fl/fl</th>
<th>NfatC&lt;sup&gt;Cre&lt;/sup&gt;,Krit1fl/+</th>
<th>NfatC&lt;sup&gt;Cre&lt;/sup&gt;,Krit1fl/fl</th>
</tr>
</thead>
<tbody>
<tr>
<td>KLF2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAPDH</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 4

<table>
<thead>
<tr>
<th></th>
<th>H&amp;E</th>
<th>Alcian Blue</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>control</td>
<td></td>
</tr>
<tr>
<td>D</td>
<td>ccm2 mutant</td>
<td></td>
</tr>
</tbody>
</table>

![Images of histological sections showing control and ccm2 mutant samples stained with H&E and Alcian Blue.]

![Bar graph showing percentage of embryos with big heart for various treatments involving MOs for krit1, klf2a/b, and adams5.]

![Images of embryos stained with green fluorescence showing control and MO treatments.]

![Bar graph showing percentage of embryos with big heart for control, klf2a/b MO, and adams5 MO treatments.]

MO: krit1  krit1 + klf2a/b  krit1 + adams5

Percentage of Embryos with Big Heart

- krit1 MO: + + +
- klf2a/b MO: - + -
- adams5 MO: - - +

G H I

K

Percentage of Embryos with Big Heart

- Control: 216(5)
- klf2a/b MO: 139(3)
- adams5 MO: 223(5)
Figure 7

**H&E**  
A: Knrt1b/+/Krt13ap3cre  
B: Knrt1b/+/Krt13ap3cre  
C: Ncol1a1cre/Krt13ap3cre  

**Alcian Blue**  
D:  
E:  
F:  

**Versican/PECAM**  
G:  
H:  
I:  

**J**  
Area jelly myocardium  
- **K**:  
- **L**:  
- **M**:  
- **N**:  

**K**  
DPEAAE  
- **70 kDa**  
GAPDH  
- **37 kDa**  

**O**  
Loss of CCM signaling  
- HEG  
- CCM1  
- CCM2  
- CCM3/GCKIII  

**MEKK3**  
**MEK5**  
**ERK5**  

↓ cardiac jelly  
myocardial proliferation
Supplemental Data

Figure S1

**Figure S1.** *Nfatc1*<sup>Cre</sup> drives endothelial recombination in the heart but not in branchial arch arteries or peripheral vessels (related to Figure 1). A, B. Analysis of *Nfatc1*<sup>Cre</sup>;R26R-YFP animals at E10.5 reveals uniform expression of YFP in the endocardium. C-F. *Nfatc1*<sup>Cre</sup>
is not active in the endothelial cells that line the branchial arch arteries at E10.5. **G-K.** Analysis of \( \text{Nfatc}^{\text{Cre}};\text{R26R-YFP} \) animals at E14.5 reveals endothelial YFP expression in the proximal aorta and pulmonary artery but not in the descending aorta. **L-R.** Analysis of \( \text{Nfatc}^{\text{Cre}};\text{R26R-YFP} \) animals at P1 reveals YFP expression in endothelial cells of the cardiac chambers (L, M) and coronary arteries (N), but not the vasculature of the kidney (O, P) or liver (Q, R). BAA, branchial arch artery; AA, ascending aorta; PA, pulmonary artery; DA, descending aorta; CA, coronary artery. Scale bars indicate 100 µm.
Figure S2. Survival of *Nfatc1*<sup>Cre</sup>:*Krit1*<sup>fl/fl</sup> embryos and gene expression in *Nfatc1*<sup>Cre</sup>:*Pdcd10*<sup>fl/fl</sup> embryos (related to Figures 1 and 2).  

**A.** *Nfatc1*<sup>Cre</sup>:*Krit1*<sup>fl/fl</sup> embryos at E12.5 and 15.5. *Nfatc1*<sup>Cre</sup>:*Krit1*<sup>fl/fl</sup> embryos were viable and visually indistinguishable from littermate controls at E12.5, but dead by E15.5.  

**B.** qPCR analysis of mRNA expression reveals increased levels of *Klf2*, *Klf4*, and KLF2/4 target genes in E10.5 *Nfatc1*<sup>Cre</sup>:*Pdcd10*<sup>fl/fl</sup> compared with *Nfatc1*<sup>Cre</sup>:*Pdcd10*<sup>fl/+</sup> and *Pdcd10*<sup>fl/+</sup> littermate hearts like those seen with endocardial deletion of *Krit1*, but of lower magnitude.  

**C.** qPCR analysis of mRNA expression reveals increased levels of *Adamts4* and *Adamts5* with preserved levels of *versican* in E10.5 *Nfatc1*<sup>Cre</sup>:*Pdcd10*<sup>fl/fl</sup> hearts as seen following endocardial deletion of *Krit1*. N= 4 for all genotypes. * indicates P <0.05; ** indicates P<0.01; *** indicates P<0.001; **** indicates P<0.0001.
Figure S3. Characterization of klf2 and adamts5 morpholinos (related to Figure 4). A. Schematic diagram of morpholinos targeting the splice sites of the klf2a and klf2b genes in zebrafish. B. Characterization of knockdown efficiency of klf2 morpholinos by RT-PCR of 30 hpf zebrafish embryos. In all cases the lower band, indicated by green arrows, is the amplified product of the wild-type mRNA while the upper bands, indicated by red arrows, are
those of mRNAs in which intron splicing has been blocked. The *ef1a* gene was amplified as a control. **C.** Schematic diagram of morpholinos targeting the splicing acceptor and donor sites of *adamts5* genes in zebrafish. **D.** Characterization of knockdown efficiency of *adamts5* morpholinos by RT-PCR of 30 hpf zebrafish embryos. The band indicated by green arrow is the amplified product of the wild-type mRNA while the upper band indicated by a red arrow is that of mRNAs in which intron splicing has been blocked, and the lower band indicated by a red arrow is the amplification of mRNA in which exon 2 splicing is skipped. The *ef1a* gene was amplified as a control.
Figure S4

**A.** Immunodetection of tetracycline-induced expression of MEKK3-BirA and endogenous MEKK3 in hCMEC/D3 cells using anti-MEKK3 antibodies.

**B.** MS/MS spectrum of an identified CCM2 peptide, TQDPGISPSQLCAESSR. This peptide was doubly charged, and two fragment b and y ions (labeled by red and blue) were observed in the generated spectrum.

**C.** Mass spectrometry identification result of CCM2. Six unique tryptic CCM2 peptides (total eight peptide-spectrum matches) were identified. “Start-End” refers to the position of the peptide in CCM2; “Observed” indicates the m/z (mass/charge) value detected by mass spectrometry; “Mr(expt)” indicates the detected molecular weight of the peptide; “Mr(calc)” indicates the theoretical molecular weight of the peptide; “ppm” represents the mass shift between “Mr(expt)” and “Mr(calc)”; “Ion score” is the Mascot score used to identify the peptide.

**D.** Distribution of identified peptides in the CCM2 protein. Matched peptides are shown in red. The sequence coverage for CCM2 was 16%.

**E, F.** Shown are the number of peptides of the indicated proteins detected by MS/MS analysis following streptavidin pulldown of hCMEC/D3 (E) or human umbilical vein (F) endothelial cells treated with 8 ng/ml doxycycline to induce expression of either BirA or BirA-MEKK3.

---

**Figure S4.** MEKK3 interacts with CCM2 in endothelial cells (related to Figure 5). **A.** Immunodetection of tetracycline-induced expression of MEKK3-BirA and endogenous MEKK3 in hCMEC/D3 cells using anti-MEKK3 antibodies. **B.** MS/MS spectrum of an identified CCM2 peptide, TQDPGISPSQLCAESSR. This peptide was doubly charged, and two fragment b and y ions (labeled by red and blue) were observed in the generated spectrum. **C.** Mass spectrometry identification result of CCM2. Six unique tryptic CCM2 peptides (total eight peptide-spectrum matches) were identified. “Start-End” refers to the position of the peptide in CCM2; “Observed” indicates the m/z (mass/charge) value detected by mass spectrometry; “Mr(expt)” indicates the detected molecular weight of the peptide; “Mr(calc)” indicates the theoretical molecular weight of the peptide; “ppm” represents the mass shift between “Mr(expt)” and “Mr(calc)”; “Ion score” is the Mascot score used to identify the peptide. **D.** Distribution of identified peptides in the CCM2 protein. Matched peptides are shown in red. The sequence coverage for CCM2 was 16%. **E, F.** Shown are the number of peptides of the indicated proteins detected by MS/MS analysis following streptavidin pulldown of hCMEC/D3 (E) or human umbilical vein (F) endothelial cells treated with 8 ng/ml doxycycline to induce expression of either BirA or BirA-MEKK3.
Figure S5. Endocardial loss of MEKK3 impairs cardiac development but does not alter cardiac jelly (related to Figure 5).  

A. *Nfatc1<sup>Cre</sup>;Map3k3<sup>fl/−</sup>* hearts exhibit thinned myocardium and normal space between endocardial and myocardial cells at E10.5. Boxed regions are shown at higher magnification on the right. Arrows indicate the endocardial-myocardial gap.  

B. Immunostaining reveals preserved levels of versican in the E10.5 *Nfatc1<sup>Cre</sup>;Map3k3<sup>fl/−</sup>* heart.
Figure S6. Mekk3 levels in Nfatc1^{Cre};Krit1^{fl/fl} and Nfatc1^{Cre};Map3k3^{fl/fl} embryos (related to Figure 6). A. Hearts from Nfatc1^{Cre};Krit1^{fl/fl} and control embryos were harvested at E10.5 and qPCR performed to measure Mekk3 (Map3k3) mRNA levels. N=3; P>0.05. B. Generation of the Map3k3^{fl} allele. A targeting vector was constructed by recombinase mediated cloning to introduce loxP sites in introns 8 and 15. These were used to target Art B6.3.5 (C57BL/6 NTac) ES cells (top). Positive colonies were identified by Southern blotting and the presence of the point mutation confirmed by Southern bolts of genomic DNA digested with Bam HI using 5’ and 3’ probe.
3’ probes external to the targeting vector (bottom). **C.** MEKK3 protein levels are reduced in *Map3k3*^{+/−} hearts. MEKK3 protein was detected using western blotting in E10.5 embryo hearts from littermates with the indicated genotypes. *Map3k3*^{+/−} animals were generated by crossing *Map3k3*^{+/fl} animals to EIIA-Cre transgenic animals to drive global gene deletion.
Figure S7. Characterization of \textit{map3k3} morpholinos (related to Figure 7). \textbf{A.} Schematic diagram of the zebrafish \textit{map3k3} allele and the exon 12 donor site targeted by \textit{map3k3} morpholinos. \textbf{B.} Characterization of knockdown efficiency of \textit{map3k3} morpholinos by RT-PCR of 30 hpf zebrafish embryos. The upper band, indicated by a green arrow, is the amplified product of the wild-type mRNA while the lower band, indicated by a red arrow, is that of
mRNAs in which intron splicing has been blocked. The $ef1a$ gene was amplified as a control.

C. Analysis of Fli1-GFP transgenic zebrafish reveals no disruption in vascular development in 72 hpf zebrafish embryos treated with low dose morpholinos targeting $krit1$ and/or $map3k3$. 
Table S1.

Live offspring of intercrosses between \( Nfatc1^{\text{Cre}};Krit1/Ccm2/Pdcd10/Map3k3^{\text{fl/+}} \) animals and \( Krit1/Ccm2/Pdcd10/Map3k3^{\text{fl/fl}} \) animals were genotyped at the indicated timepoints (related to Figures 1, 2 and 5).

<table>
<thead>
<tr>
<th></th>
<th>E10.5</th>
<th>E12.5</th>
<th>E14.5</th>
<th>P0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>60</td>
<td>18</td>
<td>24</td>
<td>37</td>
</tr>
<tr>
<td>( Krit1^{\text{fl/+}} )</td>
<td>21</td>
<td>5</td>
<td>9</td>
<td>14</td>
</tr>
<tr>
<td>( Krit1^{\text{fl/fl}} )</td>
<td>10</td>
<td>6</td>
<td>7</td>
<td>13</td>
</tr>
<tr>
<td>( Nfatc1-\text{Cre};Krit1^{\text{fl/+}} )</td>
<td>13</td>
<td>3</td>
<td>8</td>
<td>10</td>
</tr>
<tr>
<td>( Nfatc1-\text{Cre};Krit1^{\text{fl/fl}} )</td>
<td>16</td>
<td>4</td>
<td>0*</td>
<td>0**</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>E10.5</th>
<th>E12.5</th>
<th>P0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>16</td>
<td>9</td>
<td>27</td>
</tr>
<tr>
<td>( Ccm2^{\text{fl/+}} )</td>
<td>4</td>
<td>1</td>
<td>6</td>
</tr>
<tr>
<td>( Ccm2^{\text{fl/fl}} )</td>
<td>5</td>
<td>2</td>
<td>13</td>
</tr>
<tr>
<td>( Nfatc1-\text{Cre};Ccm2^{\text{fl/+}} )</td>
<td>3</td>
<td>3</td>
<td>8</td>
</tr>
<tr>
<td>( Nfatc1-\text{Cre};Ccm2^{\text{fl/fl}} )</td>
<td>4</td>
<td>3</td>
<td>0*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>E10.5-12.5</th>
<th>E14.5</th>
<th>E15.5-17.5</th>
<th>P0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>66</td>
<td>29</td>
<td>12</td>
<td>24</td>
</tr>
<tr>
<td>( Pdcd10^{\text{fl/+}} )</td>
<td>13</td>
<td>11</td>
<td>3</td>
<td>9</td>
</tr>
<tr>
<td>( Pdcd10^{\text{fl/fl}} )</td>
<td>19</td>
<td>9</td>
<td>6</td>
<td>9</td>
</tr>
<tr>
<td>( Nfatc1-\text{Cre};Pdcd10^{\text{fl/+}} )</td>
<td>17</td>
<td>4</td>
<td>3</td>
<td>6</td>
</tr>
<tr>
<td>( Nfatc1-\text{Cre};Pdcd10^{\text{fl/fl}} )</td>
<td>19</td>
<td>5</td>
<td>0*</td>
<td>0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>E10.5</th>
<th>E11.5</th>
<th>E14.5</th>
<th>P1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>100</td>
<td>55</td>
<td>51</td>
<td>54</td>
</tr>
<tr>
<td>( Map3k3^{\text{fl/+}} )</td>
<td>29</td>
<td>15</td>
<td>16</td>
<td>14</td>
</tr>
<tr>
<td>( Map3k3^{\text{fl/-}} )</td>
<td>29</td>
<td>23</td>
<td>11</td>
<td>19</td>
</tr>
<tr>
<td>( Nfatc1-\text{Cre};Map3k3^{\text{fl/+}} )</td>
<td>23</td>
<td>12</td>
<td>24</td>
<td>21</td>
</tr>
<tr>
<td>( Nfatc1-\text{Cre};Map3k3^{\text{fl/-}} )</td>
<td>19</td>
<td>5</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

* P<0.05; **P<0.001
Gene expression analysis
Total RNA was isolated with RNeasy micro kit (Qiagen). Affymatrix mouse gene 2.0st chips were used for microarray analysis. For qPCR analysis, cDNA was synthesized from 1 μg total RNA using the Superscript III Reverse Transcriptase (Invitrogen). Real-time PCR was performed in Power SYBR Green PCR Master Mix (Applied Biosciences) using the primers listed below:

mKlf2 Forward - 5’- CGCCTCGGGTTCAATTTC -3’
mKlf2 Reverse - 5’- AGCTACATTTGCGGTTCTTCTT -3’
mKlf4 Forward - 5’- GTGCCCCTACTACAGGTCGGTGT -3’
mKlf4 Reverse - 5’- GTCTGTTGAACCTCCTCGGTCT -3’
mAqp1 Forward - 5’- CATCACCTCCTCCAGTGTCGGTGTTCT -3’
mAqp1 Reverse - 5’- CAGTACAGCGCTCAGAGTGCTGC -3’
mJam2 Forward - 5’- GATCGTCGGCTTGGACTATC -3’
mJam2 Reverse - 5’- GTGACTTTCTTGGAGGTTCTG -3’
mThbd Forward - 5’- CTCTCCGCACATGCAGGCAG -3’
mThbd Reverse - 5’- GAGACGCGACTGTCATCAATGT -3’
mPalmd Forward - 5’- ATCTCACAGAGGCTCTGAAAAT -3’
mPalmd Reverse - 5’- CTGCCGATTACCATCCAGGAG -3’
mNrg1 Forward - 5’- GAAGAAGCCAGGCCAGTCAAGCT -3’
mNrg1 Reverse - 5’- TGGCTGTGTTCCAGGCTGATGT -3’
mFgf9 Forward - 5’- GTTCATTGTGAGACCGATACTT -3’
mFgf9 Reverse - 5’- TGCGAAATCTCCTCCCTTCT -3’
mFgf12 Forward - 5’- ACAGCGCAGCAGCACTGTTCTT -3’
mFgf12 Reverse - 5’- CTGCTTTCCTCGTGTATGAGTTGA -3’
mFgf16 Forward - 5’- GCTCCACCTGGAGTCTTCC -3’
mFgf16 Reverse - 5’- ACTGGTCCCGGAACACATTCAAC -3’
mJag1 Forward - 5’- TGGCCGAGGTCCTACACTT -3’
mJag1 Reverse - 5’- GCCCTTCTCAATTATGCTATCAG -3’
mDII4 Forward - 5’- AGGTGCGACATTCGTTACAC -3’
mDII4 Reverse - 5’- GGGAGAGCAGAATGGCTGATA -3’
mTmem100 Forward - 5’- GACAATGGAGAGTCATAAAC -3’
mTmem100 Reverse - 5’- GTGACGAGGAGTTCCG -3’
mVersican Forward - 5’- ACTAACCACATCACTACATA -3’
mVersican Reverse - 5’- ACTTTTCCAGAGAAGGAGCTTT -3’
mHas2 Forward - 5’- TGGGGTGGAAAGAGAAGT -3’
mHas2 Reverse - 5’- ACAGATGAGGCGGGTCAAGAC -3’
mAdamts1 Forward - 5’- CTCTCACCCCTCGGAATTTCCTG -3’
mAdamts1 Reverse - 5’- GGAGCCACATAATCTCGTCTG -3’
mAdamts4 Forward - 5’- CAGTGCCCGATCTCAG -3’
mAdamts4 Reverse - 5’- GAGTCAGGGCAGGAGTCAG -3’
mAdamts5 Forward - 5’- CGACCCCTGAAGAATTTGTCG -3’
mAdamts5 Reverse - 5’- CGTCAGAAGAGGCGCAAGT -3’
mAdamts9 Forward - 5’- TGGAGCTGCTGAAGAAGCG -3’
mAdamts9 Reverse - 5’- ACCATTGAGTTGATGTTTC -3’

Biotinylation of BirA-MEKK3 interacting proteins in live endothelial cells.
MEKK3 was PCR-amplified from pCMV5-MEKK3 (Addgene plasmid 12186). HA-BirA was PCR-amplified from mycBiolID (Addgene plasmid 35700). The two fragments were ligated to create HA-BirA-Mekk3 and cloned into the NotI and MluI sites in the pLVX-TRE3G vector (Invitrogen). For a control, BirA-HA was PCR-amplified from MCS-BirA(R118G)-HA (Addgene plasmid 36047), and cloned into the Apal and NotI sites in the pLVX-TRE3G vector.

hCMEC/D3, an immortalized human brain microvessel endothelial cell line, was grown as previously described (Weksler et al., 2005), cotransduced with both the LVX-TRE3G and LVX-Tet3G lentiviruses, and selected by G418 and puromycin. Stably transduced hCMEC/D3 cells were cultured in doxycycline-containing medium (8 ng/ml) for 3 days to express BirA-Mekk3, biotinylation induced as previously described (Roux et al., 2012), and biotinylated proteins immunoprecipitated.

Identification of BirA-MEKK3 interacting proteins using NanoLC-MS/MS analysis

The beads were resuspended in 30ul urea solution (8M urea, 75mM NaCl and 50mM Tris-HCl, pH8.3). DTT (10mM) and iodoacetamide (40mM) were added sequentially to reduce and alkylate cysteine on proteins. The solution was diluted to 1.5M urea using 50mM Tris-HCl (pH8.3). Trypsin (Promage) was added at a ratio of 1:50 (w/w) and proteins were digested overnight at room temperature. The beads were kept rotated on a rotator during all above steps. After digestion, peptides were desalted using Sep-Pak C18 cartridges (Waters) and the eluates were lyophilized.

NanoLC-MS/MS analysis: NanoLC-MS/MS was performed on a Q Exactive (Thermo Scientific) mass spectrometer equipped with EASY-nLC 1000 HPLC. Lyophilized samples were dissolved in Buffer A (0.1% formic acid in water) and loaded to a homemade C18 analytical column (75 µm I.D. × 200 mm) packed with ReproSil-Pur C18-AQ 3 µm resin (Dr. Maisch GmbH). A 120min LC gradient from 5 to 35% Buffer B (0.1% formic acid in acetonitrile) was used to separate peptides at a flow rate of 300 nL/min. The full MS scan range was m/z 350–1600. The top 15 precursor ions were selected to perform MS/MS scans by high-energy collisional dissociation (HCD). Automated gain control (AGC) values were 1E6 and 1E5 for full MS and MS/MS scans, respectively. Normalized HCD energy was set to 22.0. Dynamic exclusion was enabled with the exclusion time of 30 sec. Lock mass calibration in full MS scan was implemented using polysiloxane ion, 371.10123.

Data analysis: The acquired MS/MS spectra were searched through Mascot engine against the human Uniprot database consisting of forward and reversed protein sequences. The precursor ion tolerance was set to 10 ppm, and the fragment ion tolerance was set to 0.02 Da. Carbamidomethylation (57.0215) of cysteine was considered as a static modification, and biotinylation (226.0776) of lysine, oxidation (226.0776) of methionine and acetylation (42.0106) of protein N-terminus were considered as dynamic modifications. 1.0% False Discover Ratio (FDR) was used to filter the identified peptides.

Morpholino sequences

ccm1-MO: 5'- TGACCACCACCTATTATGCCC-3'
klf2a-MO: 5'- AACAGTGGCGTTTATTTACCTG-3'
klf2b-MO: 5'- TAAAATGCATTCTTACCGGTGTGAG-3'
adamts5-MO (X2a): 5'- CCCGCACAGATCCTGAATACACACA-3'
adamts5-MO (X2d): 5'- GTCTATGATCCGTCTGTGTACCGAT-3'
map3k3-MO 5'-AAACATGTACCTTGCTGGTCTCTGG-3'

**Primers used for qPCR analysis of cultured human endothelial gene expression**

**MAP3K3** Forward: 5’-AGGCATTAGACTCGATCATGAAG-3’
**MAP3K3** Reverse: 5’-CTCCCCATTGTGGTTCAAACCTTG-3’
**KLF2** Forward: 5’-CTACACCAAGAGTTGCATCTG-3’
**KLF2** Reverse: 5’-CCGTGTGCTTTTCGGTAGTG-3’
**KLF4** Forward: 5’-AGAGTTCCCATCTCAAGGCA-3’
**KLF4** Reverse: 5’-GTCAGTTCATCTGAGCGGG-3’
**ADAMTS4** Forward: 5’-CTGACTTCCTGGACAATGGC-3’
**ADAMTS4** Reverse: 5’-GCGGTCAAGCATCATAAGTCT-3’

**References for Supplemental Experimental Procedures**
